Essity Reports Q2 Growth Amid Volatile Market Conditions
Essity posted a 2.6% increase in net sales to SEK 35,061 million for the second quarter of 2026, navigating a landscape defined by geopolitical instability and rising input costs. While organic growth reached 0.3%, the hygiene and health company faced bottom-line pressure as EBITA slipped to SEK 4,105 million.
CEO Ulrika Kolsrud attributed the sales momentum to volume gains and a refined product mix, particularly within the Health & Medical, Personal Care, and Professional Hygiene divisions. Despite these gains, the Consumer Tissue segment struggled with lower prices and volumes, failing to fully absorb inflationary pressures. The firm reported an EBITA margin of 13.4%, slightly down from 13.7% in the same period last year.
To counter cost headwinds, Essity is leaning into operational efficiency and technological integration. The company recently deployed an agentic AI solution for procurement and is using machine learning to shorten product development cycles. These moves complement a new organizational structure designed to sharpen customer focus. With a SEK 3 billion share buyback program underway, management is betting on portfolio optimization and continued innovation to sustain shareholder value through the second half of the year.
Comments (0)
No comments yet. Be the first!